{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022medrxiv;2020.07.05.20145888v2\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2020.07.05.20145888v2\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022medrxiv;2020.07.05.20145888v2\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__dn-cpI1YtkU_iLHgA5WhlkxgYWyat_IxjF_B-WSYrpE__a9hIbt0eaZ7d5nhwnm2weG8R_2eXK4EvoOx9dOxouHE__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-article-tab-full-text\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAbstract\u003C\/h2\u003E\u003Cdiv id=\u0022sec-1\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-3\u0022\u003E\u003Cstrong\u003EBackground\u003C\/strong\u003E To accurately measure seroprevalance in the population, both the expected immune response as well as the assay performances have to be well characterised. Here, we describe the collection and initial characterisation of a blood and saliva biobank obtained after the initial peak of the SARS-CoV-2 pandemic in Switzerland.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-2\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-4\u0022\u003E\u003Cstrong\u003EMethods\u003C\/strong\u003E Two laboratory ELISAs measuring IgA \u0026amp; IgG (Euroimmun), and IgM \u0026amp; IgG (Epitope Diagnostics) were used to characterise the biobank collected from 349 re- and convalescent patients from the canton of Basel-Landschaft.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-5\u0022\u003E\u003Cstrong\u003EFindings\u003C\/strong\u003E The antibody response in terms of recognized epitopes is diverse, especially in oligosymptomatic patients, while the average strength of the antibody response of the population does correlate with the severity of the disease at each time point.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-6\u0022\u003E\u003Cstrong\u003EInterpretation\u003C\/strong\u003E The diverse immune response presents a challenge when conducting epidemiological studies as the used assays only detect \u003Cem\u003E\u223c\u003C\/em\u003E90% of the oligosymptomatic cases. This problem cannot be rectified by using more sensitive assay setting as they concomitantly reduce specificity.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-5\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-7\u0022\u003E\u003Cstrong\u003EFunding\u003C\/strong\u003E Funding was obtained from the \u201cAmt f\u00fcr Gesundheit\u201d of the canton Basel-Landschaft, Switzerland.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-6\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E1. Introduction\u003C\/h2\u003E\u003Cp id=\u0022p-20\u0022\u003EEffective host responses to viral infections, including those to coronaviruses, are driven by adaptive immunity [\u003Ca id=\u0022xref-ref-1-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E]. For endemic or previously emerging coronaviruses, the antibody response has been correlated with protection from re-infection for a varying period of time. In SARS-CoV-2 infections, most studies on antibody kinetics are based on severe or hospitalized patients, even though subclinical or even oligosymptomatic patients represent the majority of cases. Less severe cases of SARS-CoV-2 (as well as other endemic CoVs) are associated with lower antibody responses, and therefore pose a challenge for accurate detection using serological assays.\u003C\/p\u003E\u003Cp id=\u0022p-21\u0022\u003EHowever, one of the most important correlates of immunological protection is the presence of neutralizing antibodies, which is preferably measured by using functional assays with replication competent virus [\u003Ca id=\u0022xref-ref-2-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E]. For COVID-19 patients, such assays are time consuming and must be conducted in Biosafety Level 3 facilities, which renders them infeasible for wide-scale testing. Some alternative functional assays are based on pseudotyped or chimeric viral particles [\u003Ca id=\u0022xref-ref-3-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E], but these reagents are neither trivial to produce nor do they scale to large sample sizes. The most feasible alternative assays are therefore binding assays, such as enzyme-linked immunosorbent assays (ELISA), and preferably report on the quantity of antibodies binding to neutralizing epitopes such as the receptor binding domain (RBD) of the spike protein [\u003Ca id=\u0022xref-ref-4-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003ECurrent clinically approved ELISA tests either bind to the nucelocapsid (NCP) protein or (part of) the spike protein (which includes the RBD). Both of these proteins, but especially the NCP, are known to generate a strong host immune response in other beta-coronaviruses [\u003Ca id=\u0022xref-ref-5-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E]. In contrast, nearly all neutralising antibodies against SARS-CoV-2 discovered to date bind to the small RBD portion of the spike protein [\u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-8-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E], and currently available commercial assays indeed insufficiently predict neutralisation [\u003Ca id=\u0022xref-ref-2-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E]. The presence and characterization of antibody responses in COVID-19 patients by serological assays has been described in several reports [\u003Ca id=\u0022xref-ref-9-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-10-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-11-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-13-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-14-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E]; a key observation is that across many patients, antibodies are detected at \u003Cem\u003E\u223c\u003C\/em\u003E 10 days post-onset of symptoms.\u003C\/p\u003E\u003Cp id=\u0022p-23\u0022\u003EThe performance of assays is characterized by their sensitivity and specificity [\u003Ca id=\u0022xref-ref-15-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-15\u0022\u003E15\u003C\/a\u003E]. To-date, most commercial ELISA performance validations were obtained from biobanks relying on hospitalised patients; this positive patient cohort will likely have higher antibody levels than milder, non-hospitalized patients [\u003Ca id=\u0022xref-ref-16-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-16\u0022\u003E16\u003C\/a\u003E]. This is also observed for SARS-CoV-2 infections [\u003Ca id=\u0022xref-ref-17-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-17\u0022\u003E17\u003C\/a\u003E]. It is thus unclear if the available tests are sufficiently sensitive to also detect oligosymptomatic cases.\u003C\/p\u003E\u003Cp id=\u0022p-24\u0022\u003EHere, we describe the collection and initial analysis of a blood biobank representative for the observed COVID-19 symptomatic range in the population of Switzerland. The positive cohort in this biobank consists of 341 samples obtained from participants determined to have SARS-CoV-2 (PCR-positive test) in various symptomatic and post-symptomatic stages. The negative cohorts include 115 samples obtained from PCR-negative tested participants, and 150 samples of blood donors from the 2016\/17 flu season. The distribution in age and disease severity in this biobank is similar to that reported for other areas in Western Europe. For each sample, we measured the antibody response toward the NCP and S1 proteins using the ELISA tests for IgM and IgG from Epitope Diagnostics and IgA and IgG from Euroimmun, and characterized the performance of these assays. The specificity of both the Euroimmun IgG and the Epitope Diagnostics IgM assays was close to 100%, while the other two tests showed specificities of \u003Cem\u003E\u223c\u003C\/em\u003E 96% and lower. The sensitivity of the IgA and IgG tests was only sufficient to detect \u003Cem\u003E\u223c\u003C\/em\u003E 90% of the cases, while the IgM test only detected \u003Cem\u003E\u223c\u003C\/em\u003E 50%. Previous studies reported a low and late IgM response, especially in less severe COVID-19 patients [\u003Ca id=\u0022xref-ref-10-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-11-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E], which might partially explain the low IgM test sensitivity. Taken together, our data indicates that the immune response in oligosymptomatic patients is diverse and ill captured with the two employed serological assays.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-7\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E2. Materials \u0026amp; methods\u003C\/h2\u003E\u003Cdiv id=\u0022sec-8\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.1. Ethics statement\u003C\/h3\u003E\u003Cp id=\u0022p-25\u0022\u003EThis study is part of the project \u2018COVID-19 in Baselland Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 specific Antibody Responses (SERO-BL-COVID-19)\u2019 approved by the ethics board \u201cEthikkommission Nordwestund Zentralschweiz (EKNZ)\u201d, Hebelstrasse 53, 4056 Basel representative of Swissethics under the number (2020-00816).\u003C\/p\u003E\u003Cp id=\u0022p-26\u0022\u003EEvery participant has received a written informed consent at least 24 hours before participating in this study (attached original document in German language). The participants had to sign the written informed consent and needed to show it in order to be given access to the test facility. The participants could withdraw their participation at any time without stating any reason.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-9\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.2. Collection of samples\u003C\/h3\u003E\u003Cdiv id=\u0022sec-10\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003E2.2.1. Blood Collection\u003C\/h4\u003E\u003Cp id=\u0022p-27\u0022\u003EVenous blood was taken by puncturing a disinfected cubital or similar area using a BD safety-lock system into a vacutainer. In total, 10\u201312 mL each for EDTA-blood serum was taken. The blood collection was performed by a medical assistant or nurse. After blood collection, the samples were either transferred to the diagnostic lab or directly processed on site in the make-shift laboratory.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-11\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003E2.2.2. Saliva Collection\u003C\/h4\u003E\u003Cp id=\u0022p-28\u0022\u003ESaliva was collected non-invasively using the dedicated Salivette tubes (Sarstedt Cat. # 51.1534). In short, the participant delivered saliva into an adsorbent filter, which was then placed by the participant in the Salivette tube. After handover to the medical staff, the saliva was centrifuged on site at 4\u003Csup\u003E\u003Cem\u003E\u00b0\u003C\/em\u003E\u003C\/sup\u003EC using 1,000\u003Cem\u003E\u00d7\u003C\/em\u003E g for 2 min to remove cells and debris. The tube was then rapidly frozen using a salted ice-water bath and stored at \u003Cem\u003E\u2212\u003C\/em\u003E20\u003Csup\u003E\u003Cem\u003E\u00b0\u003C\/em\u003E\u003C\/sup\u003EC before transporting to the lab on dry ice and storage at \u003Cem\u003E\u2212\u003C\/em\u003E80\u003Csup\u003E\u003Cem\u003E\u00b0\u003C\/em\u003E\u003C\/sup\u003EC until further use.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-12\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003E2.2.3. Plasma and PBMC isolation and cell cryopreservation\u003C\/h4\u003E\u003Cp id=\u0022p-29\u0022\u003EDensity gradient separation was used in peripheral blood mononuclear cell (PBMC) isolation. 12 mL of fresh donor blood was received in 3\u003Cem\u003E\u00d7\u003C\/em\u003E 4 mL plastic whole blood tubes with spray-coated K\u003Csub\u003E2\u003C\/sub\u003EEDTA BD Vacutrainer\u2212 (Becton Dickinson, Cat. # 367844). The whole blood was diluted in 1:1 ratio with 12 mL of PBS (w\/o Ca\u003Csup\u003E2+\u003C\/sup\u003E and Mg\u003Csup\u003E2+\u003C\/sup\u003E). The total volume of diluted blood (24 mL) was gently and slowly layered on 14 mL of Ficoll Lymphoprep\u003Csup\u003E\u003Cem\u003ET M\u003C\/em\u003E\u003C\/sup\u003E (STEMCELL, Cat. # 07861). Samples were centrifuged at 400\u003Cem\u003E\u00d7\u003C\/em\u003E g 40 min, 22\u003Csup\u003E\u003Cem\u003E\u00b0\u003C\/em\u003E\u003C\/sup\u003EC, no brakes. 14 mL of plasma was transferred in a 15 mL conical tube and stored at 4\u003Csup\u003E\u003Cem\u003E\u00b0\u003C\/em\u003E\u003C\/sup\u003EC. The layer of mononuclear cells was aspirated and transferred in a 50 mL conical tube containing 25 mL of PBS (w\/o Ca\u003Csup\u003E2+\u003C\/sup\u003E and Mg\u003Csup\u003E2+\u003C\/sup\u003E). Cells were washed 300\u003Cem\u003E\u00d7\u003C\/em\u003E g 8 min, 22\u003Csup\u003E\u003Cem\u003E\u00b0\u003C\/em\u003E\u003C\/sup\u003EC, with brakes. Washing was repeated with an additional 25 mL of PBS (w\/o Ca\u003Csup\u003E2+\u003C\/sup\u003E and Mg\u003Csup\u003E2+\u003C\/sup\u003E). Mononuclear cells were subsequently resuspended in 1 mL of freezing media (heat inactivated FBS supplemented with 10% DMSO) and aliquoted into two 1.5 mL cryogenic tubes (Nalgene System, Thermo Scientific, Cat. # 5000-1020). The cryogenic tubes were put into freezing containers Mr.Frosty\u2212 (Thermo Scientific, Cat. # 5100-0001) and the containers were immediately placed into an \u003Cem\u003E\u2212\u003C\/em\u003E80\u003Csup\u003E\u003Cem\u003E\u00b0\u003C\/em\u003E\u003C\/sup\u003EC freezer for 24 hrs, and then transferred into a liquid nitrogen tank.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-13\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003E2.2.4. Point of care validation\u003C\/h4\u003E\u003Cp id=\u0022p-30\u0022\u003ETo perform the point of care test (POCT) validation, a capillary blood sample was taken from each subject by puncturing the end of a finger and taking the blood with a micro pipette. Immediately after collecting, the blood was put in the lateral flow chamber of the POCT and after 15 minutes the result was visually scored as positive or negative by the medical assistant. Additionally, the tests were imaged using a Nikon D5000 camera.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-14\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003E2.2.5. Blood donor cohort\u003C\/h4\u003E\u003Cp id=\u0022p-31\u0022\u003ESamples from nonremunerated blood donors originate from the Swiss cantons of Thurgau, Basel, Bern, Waadt and Geneva, and were taken during the pre-pandemic period 16th and 17th December 2016. These samples were frozen as EDTA plasmas on microtiterplates for \u003Cem\u003E\u2212\u003C\/em\u003E20\u003Csup\u003E\u003Cem\u003E\u00b0\u003C\/em\u003E\u003C\/sup\u003EC.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-15\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.3. ELISA analysis\u003C\/h3\u003E\u003Cp id=\u0022p-32\u0022\u003EThe following four commercially available immunoassays were characterized in the study: the Anti-SARS-CoV-2-ELISA-IgA (Euroimmun AG, L\u00fcbeck, # EI 2606-9601 A), the Anti-SARS-CoV-2-ELISA-IgAG (Euroimmun AG, L\u00fcbeck, # EI 2606-9601 G), the EDI Novel Coronavirus COVID-19 IgM ELISA kit (Epitope Diagnostics, Inc., # KT-1033) and the EDI Novel Coronavirus COVID-19 IgG ELISA kit (Epitope Diagnostics, Inc., # KT-1032). All ELISA kits were CE and IVD labeled.\u003C\/p\u003E\u003Cp id=\u0022p-33\u0022\u003ETo enable a quantitative comparison between ELISA experiments, we calculated fold changes in OD relative to the assay- and run-specific cut-off values (OD\u003Csub\u003Esample\u003C\/sub\u003E\/OD\u003Csub\u003Ecut-off\u003C\/sub\u003E), where OD\u003Csub\u003Ecut-off\u003C\/sub\u003E = 1.1\u003Cem\u003E\u00d7\u003C\/em\u003EOD\u003Csub\u003Ecal\u003C\/sub\u003E for both Euroimmun ELISAs, OD\u003Csub\u003Ecut-off\u003C\/sub\u003E = (1.1 + 0.18)\u003Cem\u003E\u00d7\u003C\/em\u003EOD\u003Csub\u003ENC\u003C\/sub\u003E for EDI IgG and OD\u003Csub\u003Ecut-off\u003C\/sub\u003E = (1.1 + 0.10)\u003Cem\u003E\u00d7\u003C\/em\u003EOD\u003Csub\u003ENC\u003C\/sub\u003E for EDI IgM, where OD\u003Csub\u003Ecal\u003C\/sub\u003E and OD\u003Csub\u003ENC\u003C\/sub\u003E are calibration respectively average negative control values as described by the manufacturers. Note that fold changes are not comparable between Euroimmun and EDI ELISA test kits because the assays show large differences in dynamic range and saturation. Detailed calculation can be found in the supplementary methods.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-16\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.4. Statistical analysis\u003C\/h3\u003E\u003Cp id=\u0022p-34\u0022\u003EPatient data and results of POCTs were originally stored in the REDCap database system of the Canton Hospital Basel-Landschaft. Results from ELISA tests were entered into Excel worksheets. All data were preprocessed and a common database created using in-house scripts in R [\u003Ca id=\u0022xref-ref-18-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E]. Statistical analysis and creation of figures and tables was carried out using R; binomial confidence intervals are 95%-Clopper-Pearson intervals calculated using exactci() from package PropCIs [\u003Ca id=\u0022xref-ref-19-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-19\u0022\u003E19\u003C\/a\u003E]. A refresher for the calculation of specificity and sensitivity calculation can be found in the supplementary methods.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-17\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.5. Role of the funding source\u003C\/h3\u003E\u003Cp id=\u0022p-35\u0022\u003EThe sponsor had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-18\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E3. Results\u003C\/h2\u003E\u003Cdiv id=\u0022sec-19\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.1. Study design \u0026amp; cohorts\u003C\/h3\u003E\u003Cp id=\u0022p-36\u0022\u003EThe goal of our study design was to collect a representative cohort of COVID-19 disease manifestation during the first wave of COVID-19 in the canton Basel-Landschaft, Switzerland. During the initial phase of the pandemic, only people in risk groups showing symptoms were tested; later, testing was extended to all people showing symptoms and 5311 people had been tested in the canton at the beginning of study recruitment, with 802 (15.1%) positive and 4509 (84.9%) negative PCR test results. The cases were mostly observed close to or in areas with a high frequency of commuting to the city of Basel, but the ratio of positive tests showed no apparent bias for or against rural communities.\u003C\/p\u003E\u003Cp id=\u0022p-37\u0022\u003EAll RT-PCR-tested individuals were eligible for participation except when they were \u003Cem\u003E\u0026lt;\u003C\/em\u003E18 years of age, had a severely compromised immune system, were hospitalized at the time of sample collection, or were deceased. From these, 349 positive individuals committed to participating in the study, and 111 negative individuals were randomly selected. We aimed for sufficient sample size for two positive cohorts: an \u2018acute\u2019 cohort with diagnosed COVID-19 up to 12 days before study entry, and a \u2018convalescent\u2019 cohort with more than 12 days between positive diagnosis and study entry.\u003C\/p\u003E\u003Cp id=\u0022p-38\u0022\u003EIndividuals were continuously recruited during a 2 week window from 11. April 2020 to 22. April 2020 and visited the \u2018Abkl\u00e4rungsstation COVID-19\u2019 in M\u00fcnchenstein, Switzerland. The medical history and the status were recorded in a doctors interview, the vital parameters were acquired, and saliva and blood samples were collected. All participants of the positive cohort were guided through the building, while the negative cohort was examined in a make-shift field hospital erected next to the building to minimize the danger of infection with COVID-19. Participant characteristics are summarized in \u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/245900\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/245900\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/245900\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1:\u003C\/span\u003E \u003Cp id=\u0022p-39\u0022 class=\u0022first-child\u0022\u003ECharacteristics of patients included in the study.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-40\u0022\u003EDistribution of ages and gender for the positive cohort are similar to the age and gender structure of the canton, except for the age between 40\u201365 which are over-represented and \u003Cem\u003E\u0026gt;\u003C\/em\u003E80 which are under-represented (\u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E and Supplementary Figure 1). From the 349 positive participants, 35 (10%) were bedridden during the acute disease, 62 (18%) required help for their daily activities, while 244 (72%) had no restrictions. Similar distributions are reported elsewhere. All age groups were affected equally, however severe cases were more pronounced in the older population. Increasing disease severity correlated with the experienced symptoms; bedridden cases suffered approximately 10 or more days, cases requiring help \u003Cem\u003E\u223c\u003C\/em\u003E10 days, and the oligosymptomatic cases between 5 to 15 days.\u003C\/p\u003E\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/245901\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/245901\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/245901\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2:\u003C\/span\u003E \u003Cp id=\u0022p-41\u0022 class=\u0022first-child\u0022\u003EAge structure of study cohort stratified by severity and by duration of symptoms. Last row shows distribution of ages 15+ in canton of Basel-Land in 2019 for reference.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/07\/09\/2020.07.05.20145888\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Overview on ELISA results. Epitope Diagnostics (EDI) and Euroimmun assays were performed with serum from 607 individuals. The negative cohort consists of 150 serum samples collected during the 2016\/17 influenza period and 110 serum samples from PCR-negative individuals from 2020. Positive cases are stratified by days post symptoms onset (left) and additionally stratified by disease severity (right). Fold changes are defined as the ratio between measured OD and the classification cut-off OD specified by the manufacturer. Grey area indicates the range where serum samples are classified as uncertain; samples above (below) this area are classified as positive (negative).\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-825418430\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;span xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot; class=\u0026quot;caption-title\u0026quot;\u0026gt;Overview on ELISA results.\u0026lt;\/span\u0026gt; Epitope Diagnostics (EDI) and Euroimmun assays were performed with serum from 607 individuals. The negative cohort consists of 150 serum samples collected during the 2016\/17 influenza period and 110 serum samples from PCR-negative individuals from 2020. Positive cases are stratified by days post symptoms onset (left) and additionally stratified by disease severity (right). Fold changes are defined as the ratio between measured OD and the classification cut-off OD specified by the manufacturer. Grey area indicates the range where serum samples are classified as uncertain; samples above (below) this area are classified as positive (negative).\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 1:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/07\/09\/2020.07.05.20145888\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022188\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 1:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/07\/09\/2020.07.05.20145888\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022188\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/07\/09\/2020.07.05.20145888\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/07\/09\/2020.07.05.20145888\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1:\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EOverview on ELISA results.\u003C\/span\u003E\u003Cp id=\u0022p-42\u0022 class=\u0022first-child\u0022\u003EEpitope Diagnostics (EDI) and Euroimmun assays were performed with serum from 607 individuals. The negative cohort consists of 150 serum samples collected during the 2016\/17 influenza period and 110 serum samples from PCR-negative individuals from 2020. Positive cases are stratified by days post symptoms onset (left) and additionally stratified by disease severity (right). Fold changes are defined as the ratio between measured OD and the classification cut-off OD specified by the manufacturer. Grey area indicates the range where serum samples are classified as uncertain; samples above (below) this area are classified as positive (negative).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-43\u0022\u003EWe use two negative cohorts; (i) samples from 150 2016\/17 influenza period blood donors, and (ii) our negative cohort. These cohorts should strengthen the specificity calculations, but also help to address cross-reactivity to viruses currently in circulation. However, the PCR test is prone to false negatives, and we therefore expect to find a small number of incorrectly diagnosed individuals. In line with the reported false negative rate of 15\u201325% [\u003Ca id=\u0022xref-ref-20-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-20\u0022\u003E20\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-21-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-21\u0022\u003E21\u003C\/a\u003E], we identified four individuals with negative PCR results but seroconverted in both Euroimmun IgG and IgA and Epitope Diagnostics (EDI) IgG. We consider these four individuals as false negative PCR results and removed them from the dataset. All results are only influenced marginally by this step.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-20\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.2. Performance characteristics of ELISA tests\u003C\/h3\u003E\u003Cdiv id=\u0022sec-21\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003E3.2.1. Sensitivity \u0026amp; specificity\u003C\/h4\u003E\u003Cp id=\u0022p-44\u0022\u003EWe performed the EDI and Euroimmun assays according to the manufacturer\u2019s instructions on all samples. The obtained data were normalized (see Material and Methods section) to make results comparable between experiments. The reported fold-changes are defined as the ratio between measured OD and the classification cut-off OD specified by the manufacturer (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E \u0026amp; Supplementary Figure 2). Positive\/negative classification was performed according to manufacturer\u2019s instructions, and the assay performance was calculated therefrom.\u003C\/p\u003E\u003Cdiv id=\u0022F2\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/07\/09\/2020.07.05.20145888\/F2.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022A: Log2-fold changes in ELISA signal for each assay by time after symptoms onset and by disease severity. Data was fitted using smoothing splines to visualize trends (figure shows fits and 95% confidence intervals). Grey area indicates the range where serum samples are classified as uncertain; samples above (below) this area are classified as positive (negative). B: Scatterplots comparing log2-fold changes in IgA vs IgG measured by Euroimmun ELISA (left), IgG measured by Euroimmun ELISA vs IgG measured by Epitope Diagnostics (EDI) ELISA (center), and Euroimmun IgA vs EDI IgG (right) by disease severity. C: As in B but with days after onset of symptoms. Fold-changes are defined as the ratio between measured OD and the classification cut-off OD specified by the manufacturer.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-825418430\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;A: Log\u0026lt;sub\u0026gt;2\u0026lt;\/sub\u0026gt;-fold changes in ELISA signal for each assay by time after symptoms onset and by disease severity. Data was fitted using smoothing splines to visualize trends (figure shows fits and 95% confidence intervals). Grey area indicates the range where serum samples are classified as uncertain; samples above (below) this area are classified as positive (negative). B: Scatterplots comparing log\u0026lt;sub\u0026gt;2\u0026lt;\/sub\u0026gt;-fold changes in IgA vs IgG measured by Euroimmun ELISA (left), IgG measured by Euroimmun ELISA vs IgG measured by Epitope Diagnostics (EDI) ELISA (center), and Euroimmun IgA vs EDI IgG (right) by disease severity. C: As in B but with days after onset of symptoms. Fold-changes are defined as the ratio between measured OD and the classification cut-off OD specified by the manufacturer.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 2:\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/07\/09\/2020.07.05.20145888\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022361\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 2:\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/07\/09\/2020.07.05.20145888\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022361\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/07\/09\/2020.07.05.20145888\/F2.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 2:\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/07\/09\/2020.07.05.20145888\/F2.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 2:\u003C\/span\u003E \u003Cp id=\u0022p-45\u0022 class=\u0022first-child\u0022\u003EA: Log\u003Csub\u003E2\u003C\/sub\u003E-fold changes in ELISA signal for each assay by time after symptoms onset and by disease severity. Data was fitted using smoothing splines to visualize trends (figure shows fits and 95% confidence intervals). Grey area indicates the range where serum samples are classified as uncertain; samples above (below) this area are classified as positive (negative). B: Scatterplots comparing log\u003Csub\u003E2\u003C\/sub\u003E-fold changes in IgA vs IgG measured by Euroimmun ELISA (left), IgG measured by Euroimmun ELISA vs IgG measured by Epitope Diagnostics (EDI) ELISA (center), and Euroimmun IgA vs EDI IgG (right) by disease severity. C: As in B but with days after onset of symptoms. Fold-changes are defined as the ratio between measured OD and the classification cut-off OD specified by the manufacturer.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-46\u0022\u003EWe used a patient\u2019s assignment to the PCR-positive or PCR-negative cohort together with the corresponding ELISA test result for calculating performance characteristics for all four assays. The values considering all data are shown in the top of \u003Ca id=\u0022xref-table-wrap-3-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E. We find specificities of the IgG-based assays of about 98%-99%, while IgA shows considerably lower and IgM considerably higher specificity overall. To determine potential cross-reactivity of the assays, we separately calculated the specificity from the 150 samples of the 2016 blood donor cohort (\u003Ca id=\u0022xref-table-wrap-3-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E (bottom)). Nevertheless, the histogram of all assays and data show overlap between the cohorts (Supplementary Figure 3).\u003C\/p\u003E\u003Cdiv id=\u0022T3\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/245898\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/245898\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/245898\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 3:\u003C\/span\u003E \u003Cp id=\u0022p-47\u0022 class=\u0022first-child\u0022\u003ETop: Number true positive (TP), false positive (FP), true negative (TN), false negative (FN), sensitivity (Se) and specificity (Sp) for Epitope Diagnostics (EDI) serum and plasma samples and Euroimmun ELISA serum samples for all cohorts. All samples with uncertain result were considered negative for the analysis (number of uncertain samples shown in brackets). Column IgG 1.5\u003Cem\u003E\u00d7\u003C\/em\u003E for Euroimmun corresponds to using a threshold of 1.5 instead of 1.1 for the OD-ratio. Bottom: specificity based on serum samples of negative 2016 blood donor cohort only.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-48\u0022\u003EThe IgG- and IgA-based assays show overall sensitivities above 87%, while the sensitivity of IgM is extremely low at slightly above 50%. However, the different types of antibodies act at different stages of the immune response. We therefore stratified the calculation of assay sensitivities by days after onset of symptoms into three categories: 14 days or less, 15 to 20 days, and 21 days or more (\u003Ca id=\u0022xref-table-wrap-4-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T4\u0022\u003ETable 4\u003C\/a\u003E \u0026amp; Supplementary Figure 4). Sensitivities increase with days after onset of symptoms for both IgG assays from about 50% to 95%. The sensitivity of the IgM assay remains low for all strata, while IgA already shows substantially higher sensitivities than all other assays for less than 14 days after onset of symptoms. Specifically, sensitivity is low for the EDI Diagnostics IgM assay, reaching a maximum of 64% for two to three weeks after onset of symptoms. Both IgG assays show overall sensitivities below 90%, but sensitivities increase to 95% or higher three weeks after onset of symptoms. The Euroimmun IgA sensitivity is highest among the four assays for less than two weeks after onset of symptoms with 82% and also reaches about 95% after three weeks or more after onset of symptoms.\u003C\/p\u003E\u003Cdiv id=\u0022T4\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/245896\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/245896\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/245896\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 4:\u003C\/span\u003E \u003Cp id=\u0022p-49\u0022 class=\u0022first-child\u0022\u003ESensitivity of EDI (top) and Euroimmun (bottom) ELISA stratified by days after onset of symptoms. All samples with uncertain result were considered negative for the analysis (number of uncertain samples shown in brackets).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-50\u0022\u003EWe performed the same analysis stratified by three levels of disease severity\u2014\u2018no restriction\u2019, \u2018help needed\u2019, and \u2018bedridden\u2019\u2014and combined these levels with two levels for days after onset of symptoms: short (\u003Cem\u003E\u2264\u003C\/em\u003E 21 days) or long (\u003Cem\u003E\u0026gt;\u003C\/em\u003E 21 days). The resulting sensitivities and specificities and their 95% confidence intervals are given in \u003Ca id=\u0022xref-table-wrap-5-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T5\u0022\u003ETable 5\u003C\/a\u003E. As expected, sensitivities also increase with severity of symptoms for both less and more than three weeks after onset of symptoms, but sample sizes are comparatively small for shorter time and higher severity. Notably, the IgG response is detectable in all samples of the \u2018bedridden\u2019 cohort \u003Cem\u003E\u0026gt;\u003C\/em\u003E 21 days, and is then comparable to the manufacturer\u2019s characterisation on this subset.\u003C\/p\u003E\u003Cdiv id=\u0022T5\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/245897\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/245897\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/245897\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 5:\u003C\/span\u003E \u003Cp id=\u0022p-51\u0022 class=\u0022first-child\u0022\u003ESensitivities stratified by severity of illness. All samples with uncertain result were considered negative for the analysis (number of uncertain samples shown in brackets).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-22\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003E3.2.2. Reproducibility and linearity\u003C\/h4\u003E\u003Cp id=\u0022p-52\u0022\u003EIntra-assay variability was determined by calculating the mean, standard deviation, and coefficient of variation of the measured OD ratios based in 5 replicate measurements of 8 samples with values ranging from at or below the threshold limit to about the 75% quartile in the two IgG and IgA assays (Supplementary Table 5 \u0026amp; Supplementary Figure 6). In general, reproducibility was high with coefficients of variation of 5% or smaller in samples well above the threshold. This variation increased to \u003Cem\u003E\u223c\u003C\/em\u003E 10% at or below the threshold. It is trivial but important to state that, at the threshold, this variability can lead to different classification in each repetition. Last, different samples show different variabilities in the two IgG assays, possibly indicating the difference between the binding epitope and assay manufacturing.\u003C\/p\u003E\u003Cp id=\u0022p-53\u0022\u003EWe investigated the assay linearity using two-fold serially diluted serum samples from 5 individuals with high OD values for IgG (Supplementary Figure 11). Both Euroimmun assays showed a good linearity over a dilution range of 64-fold (2\u003Csup\u003E6\u003C\/sup\u003E dilutions), while the IgG Epitope Diagnostics (EDI) assay is linear only in a 16-fold (2\u003Csup\u003E4\u003C\/sup\u003E) dilution range. Additionally, both IgG assays show good agreement along the dilutions (Supplementary Figure 10), suggesting that\u2014after normalization and scaling\u2014the IgG assays give comparable quantitative results. No data of sufficient quality was acquired for a discussion of the IgM assay (Supplementary Figure 11). Additionally, we found that the IgG, but not the IgM, assay from EDI is sensitive to haemolysis (Supplementary Figure 12).\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-23\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.3. Kinetics of seroconversion\u003C\/h3\u003E\u003Cp id=\u0022p-54\u0022\u003EOur positive cohort can give insight into the kinetics of seroconversion at the population level for different antibody types and epitopes and a broad range of disease manifestations. The two ELISA tests employ different epitopes: the EDI test recognizes the SARS-CoV-2 nucleocapsidprotein and uses IgG and IgA while the Euroimmun test recognizes the S1 portion of the spike protein using IgG and IgM.\u003C\/p\u003E\u003Cp id=\u0022p-55\u0022\u003EFor all antibody types, the strength of the response over time correlated with severity of the symptoms (\u003Ca id=\u0022xref-fig-2-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2A\u003C\/a\u003E). We only measured a well discernible IgM response in the \u201cbedridden\u201d group and a slight response in the \u201chelp needed\u201d group, while it was largely absent from the \u201cno restriction\u201d group. On the other hand, the IgA and IgG response is measurable in most samples. The average response is higher when \u201cbedridden\u201d, while similar antibody response levels are observed for \u201cno restriction\u201d and \u201chelp needed\u201d.\u003C\/p\u003E\u003Cp id=\u0022p-56\u0022\u003EIn most viral host responses, the earliest measurable response is IgM followed by IgG and IgA. Surprisingly, but in line with other reports for SARS-CoV-2 [\u003Ca id=\u0022xref-ref-10-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-11-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E] as well as observations for SARS and MERS, all three antibody types reacted within a similar timeframe. The earliest detection, within a week of symptom onset, was for IgA, followed by IgM and IgG both detected from week 2. IgM then peaked 2\u20133 weeks and IgA 3\u20134 weeks post symptom onset, while no decline for IgG was measured. The temporal order of these peaks can be expected based on the half-life time of the different antibody types in the blood.\u003C\/p\u003E\u003Cp id=\u0022p-57\u0022\u003EThese observations are further substantiated from observing the responses on the level of the individuals. Most interestingly, we find a robust IgG response against the NCP early on, whereas the response to the spike protein seems to be more prevalent at later time points (\u003Ca id=\u0022xref-fig-2-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2A\u003C\/a\u003E). However, neither IgG response is significantly different depending on the severity of the disease. The IgA response against the spike protein is produced rapidly in the absence of an IgG response but subsides at later time points when the IgG response becomes dominant.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-24\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E4. Discussion\u003C\/h2\u003E\u003Cp id=\u0022p-58\u0022\u003EHere, we describe the collection and initial characterisation of a blood bank from the affected population of the canton Basel-Landschaft, Switzerland. Almost 50% of the people fallen ill with COVID-19 participated in this study and the biobank is therefore exemplary for an outbreak in a western European community. In particular, the COVID-19 severity and symptoms in the biobank samples closely follow the reported distributions elsewhere. We might have slightly biased our cohorts toward less severe cases, by excluding samples from actively hospitalized or deceased patients. Since only 11 cases remained in the hospital at the time of recruitment, this bias is likely small. Overall, we consider the largely representative sample a strength of our biobank, as it allows us to estimate the kinetics of seroconversion and assay performance characteristics on samples closely resembling those expected in population-wide studies for sero-prevalence.\u003C\/p\u003E\u003Cp id=\u0022p-59\u0022\u003EWe find that both specificity and sensitivity are below the manufacturer\u2019s specifications for all four tests, and observe similar sensitivities only for our \u2018bedridden\u2019 group. This indicates that characterizations by the manufacturers are likely based on \u2018severe\u2019 cohorts, which limits their applicability and impairs planning of sero-prevalence studies. We also find that the IgA and IgG assays allow for quantification within a relatively narrow range: the linear range of the Euroimmun assay covers approximately a 64-fold dilution range and the EDI assay a 16-fold dilution range. When calculating sensitivities and specificities with our cohort, the IgA test shows the highest sensitivity, followed by the two IgG assays. The poor sensitivity of the IgM test is either due to the absence of a dedicated IgM response [\u003Ca id=\u0022xref-ref-22-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003E22\u003C\/a\u003E] in line with previous reports or poor test performance. The highest specificity is achieved with the Euroimmun IgG test. The specificity could be further boosted by a higher cut-off as previously reported, however accompanied by a concurrent drop in sensitivity (Supplementary Tables 14, 15, 16).\u003C\/p\u003E\u003Cp id=\u0022p-60\u0022\u003EThe average strength of the antibody response, as measured by the ratios, correlates with the severity of the disease at each time point. However, the differences vanish the longer post-symptoms onset the individuals are, and the measured amount in an individual is not predictive for the severity of the disease. Surprisingly, but similar to earlier reports, we measured that the temporal order of the response is shifted. IgA is measured within 1\u20132 weeks after symptoms onset, followed by the IgG response at week 2\u20133, while a clear IgM response is absent. Especially at earlier time points, the IgA response is stronger than the IgG response as measured using the S1 spike protein epitope in the Euroimmun assay. To fully understand what the obtained values reflect and how they correlate with diseases and protection from disease, further analyses are planned including measuring the strength to neutralize pseudo-typed viral particles and analysing the individual antibodies by sequencing the PBMCs. However, our current data help to understand the limitations of the current antibody tests on the market and serve as the basis to interpret ongoing studies on other lab assay characterization, POCT performances and PBMC sequencing.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section data-availability\u0022 id=\u0022sec-25\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData Availability\u003C\/h2\u003E\u003Cp id=\u0022p-61\u0022\u003EData are available upon request\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ack\u0022 id=\u0022ack-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAcknowledgement\u003C\/h2\u003E\u003Cp id=\u0022p-62\u0022\u003EThis study was sponsored by J\u00fcrg Sommer, head of the \u201cAmt f\u00fcr Gesundheit\u201d, and the logistics of the sample collection were provided by the crisis staff and the civil protection service of the canton Basel-Landschaft. FR is funded by the NCCR \u2018Molecular Systems Engineering\u2019. Funding for JD from the two Cantons of Basel through project grant PMB-01-17 granted by the ETH Zurich is acknowledged.\u003C\/p\u003E\u003Cp id=\u0022p-63\u0022\u003EFunding for TR, DP, BN Funding for MS\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EReferences\u003C\/h2\u003E\u003Col class=\u0022cit-list ref-use-labels\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[1].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference [1] in text\u0022 id=\u0022ref-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHuang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGarcia-Carreras\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. D.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHitchings\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EYang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKatzelnick\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERattigan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBorgert\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMoreno\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB. D.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESolomon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERodriguez-Barraquer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EA systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EmedRxiv\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[2].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-2-1\u0022 title=\u0022View reference [2] in text\u0022 id=\u0022ref-2\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.2\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAj\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMj\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EPerformance of six SARS-CoV-2 immunoassays in comparison with microneutralisation\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of clinical virology: the official publication of the Pan American Society for Clinical Virology\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E129\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E) \u003Cspan class=\u0022cit-fpage\u0022\u003E104512\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bclinical%2Bvirology%253A%2Bthe%2Bofficial%2Bpublication%2Bof%2Bthe%2BPan%2BAmerican%2BSociety%2Bfor%2BClinical%2BVirology%26rft.volume%253D129%26rft.spage%253D104512%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[3].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-3-1\u0022 title=\u0022View reference [3] in text\u0022 id=\u0022ref-3\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.3\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmidt\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWeisblum\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMuecksch\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH.-H.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHoffmann\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMichailidis\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. C.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELorenzi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMendoza\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERutkowska\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBednarski\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGaebler\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EMeasuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EbioRxiv\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[4].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference [4] in text\u0022 id=\u0022ref-4\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.4\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAmanat\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EStadlbauer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EStrohmeier\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. H.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENguyen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChromikova\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMcMahon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJiang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EArunkumar\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJurczyszak\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPolanco\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EA serological assay to detect SARS-CoV-2 seroconversion in humans\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENature medicine\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E) \u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E4\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[5].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-5-1\u0022 title=\u0022View reference [5] in text\u0022 id=\u0022ref-5\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.5\u0022 data-doi=\u002210.1128\/JCM.41.12.5781-5782.2003\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EShi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EYi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKuang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDong\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EQ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMa\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECao\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EDiagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of clinical microbiology\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E41\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2003\u003C\/span\u003E) \u003Cspan class=\u0022cit-fpage\u0022\u003E5781\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E5782\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2BClinical%2BMicrobiology%26rft.stitle%253DJ.%2BClin.%2BMicrobiol.%26rft.aulast%253DShi%26rft.auinit1%253DY.%26rft.volume%253D41%26rft.issue%253D12%26rft.spage%253D5781%26rft.epage%253D5782%26rft.atitle%253DDiagnosis%2Bof%2BSevere%2BAcute%2BRespiratory%2BSyndrome%2B%2528SARS%2529%2Bby%2BDetection%2Bof%2BSARS%2BCoronavirus%2BNucleocapsid%2BAntibodies%2Bin%2Ban%2BAntigen-Capturing%2BEnzyme-Linked%2BImmunosorbent%2BAssay%26rft_id%253Dinfo%253Adoi%252F10.1128%252FJCM.41.12.5781-5782.2003%26rft_id%253Dinfo%253Apmid%252F14662982%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiamNtIjtzOjU6InJlc2lkIjtzOjEwOiI0MS8xMi81NzgxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjAvMDcvMDkvMjAyMC4wNy4wNS4yMDE0NTg4OC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[6].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference [6] in text\u0022 id=\u0022ref-6\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP. D.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBurbelo\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF. X.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERiedo\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMorishima\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERawlings\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESmith\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDas\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EStrich\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. S.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChertow\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER. T. Davey\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJr\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. I.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECohen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ESensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EThe Journal of infectious diseases\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[7].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference [7] in text\u0022 id=\u0022ref-7\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELiu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EQ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EXia\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELing\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EXun\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENeutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[8].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-8-1\u0022 title=\u0022View reference [8] in text\u0022 id=\u0022ref-8\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.8\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. F.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERogers\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhao\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHuang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBeutler\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBurns\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW.-t.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHe\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EO.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELimbo\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESmith\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG. Song\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWoehl\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EIsolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EScience\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[9].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-9-1\u0022 title=\u0022View reference [9] in text\u0022 id=\u0022ref-9\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.9\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EOkba\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EM\u00fcller\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. H.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGeurtsvanKessel\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECorman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELamers\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER. S.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESikkema\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003Ede Bruin\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF. D.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChandler\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ESevere acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients\u003C\/span\u003E., \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEmerging infectious diseases\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E26\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[10].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-10-1\u0022 title=\u0022View reference [10] in text\u0022 id=\u0022ref-10\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.10\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESun\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY. Feng\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMo\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZheng\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EQ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPeng\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELiu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHuang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EKinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEmerging Microbes \u0026amp; Infections\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E) \u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E36\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[11].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-11-1\u0022 title=\u0022View reference [11] in text\u0022 id=\u0022ref-11\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.11\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EQ.-X.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELong\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB.-Z.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELiu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH.-J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDeng\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG.-C.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDeng\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.-K.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELiao\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.-F.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EQiu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELin\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX.-F.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECai\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EAntibody responses to SARS-CoV-2 in patients with COVID-19\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENature medicine\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E) \u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E4\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[12].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference [12] in text\u0022 id=\u0022ref-12\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.12\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EShen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhao\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EShen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDing\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHuang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EDelayed specific IgM antibody responses observed among COVID-19 patients with severe progression\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEmerging Microbes \u0026amp; Infections\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E9\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E) \u003Cspan class=\u0022cit-fpage\u0022\u003E1096\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1101\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DEmerging%2BMicrobes%2B%2526%2BInfections%26rft.volume%253D9%26rft.spage%253D1096%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[13].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-1\u0022 title=\u0022View reference [13] in text\u0022 id=\u0022ref-13\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.13\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. S.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESuthar\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. G.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZimmerman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER. C.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKauffman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMantus\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. L.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELinderman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW. H.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHudson\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVanderheiden\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENyhoff\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. W.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDavis\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAdekunle\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ERapid generation of neutralizing antibody responses in COVID-19 patients\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECell Reports Medicine\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[14].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-14-1\u0022 title=\u0022View reference [14] in text\u0022 id=\u0022ref-14\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.14\u0022 data-doi=\u002210.1038\/s41586-020-2196-x\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EW\u00f6lfel\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECorman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGuggemos\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESeilmaier\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZange\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EM\u00fcller Niemeyer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. C.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJones\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVollmar\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERothe\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EVirological assessment of hospitalized patients with COVID-2019\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENature\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E581\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E) \u003Cspan class=\u0022cit-fpage\u0022\u003E465\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E469\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNature%26rft.volume%253D581%26rft.spage%253D465%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41586-020-2196-x%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/s41586-020-2196-x\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F07%2F09%2F2020.07.05.20145888.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[15].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-15-1\u0022 title=\u0022View reference [15] in text\u0022 id=\u0022ref-15\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.15\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELathrop\u003C\/span\u003E\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFDA, Analytical validation and points for discussion\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[16].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-16-1\u0022 title=\u0022View reference [16] in text\u0022 id=\u0022ref-16\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.16\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EUbol\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. B.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHalstead\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EHow innate immune mechanisms contribute to antibodyenhanced viral infections\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClinical and Vaccine Immunology\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E17\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E) \u003Cspan class=\u0022cit-fpage\u0022\u003E1829\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1835\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DClinical%2Band%2BVaccine%2BImmunology%26rft.volume%253D17%26rft.spage%253D1829%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[17].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-17-1\u0022 title=\u0022View reference [17] in text\u0022 id=\u0022ref-17\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.17\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EXie\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDing\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGuo\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZheng\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJin\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGao\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ECharacteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of medical virology\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[18].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-18-1\u0022 title=\u0022View reference [18] in text\u0022 id=\u0022ref-18\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-2020.07.05.20145888v2.18\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ER Core Team\u003C\/span\u003E, \u003Cspan class=\u0022cit-source\u0022\u003ER: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing\u003C\/span\u003E, \u003Cspan class=\u0022cit-publ-loc\u0022\u003EVienna, Austria\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[19].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-19-1\u0022 title=\u0022View reference [19] in text\u0022 id=\u0022ref-19\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.19\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EScherer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EPropCIs: Various Confidence Interval Methods for Proportions\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ER package version 0.3-0\u003C\/abbr\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[20].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-20-1\u0022 title=\u0022View reference [20] in text\u0022 id=\u0022ref-20\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.20\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKucirka\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELauer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EO.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELaeyendecker\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBoon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELessler\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EVariation in falsenegative rate of reverse transcriptase polymerase chain reaction\u2013based SARS-CoV-2 tests by time since exposure\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnals of Internal Medicine\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[21].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-21-1\u0022 title=\u0022View reference [21] in text\u0022 id=\u0022ref-21\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.21\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EXiao\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY. X.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETong\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EFalse-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of medical virology\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E[22].\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-22-1\u0022 title=\u0022View reference [22] in text\u0022 id=\u0022ref-22\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.07.05.20145888v2.22\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMa\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZeng\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHe\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhao\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJiang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhou\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECheng\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMa\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJin\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ESerum IgA, IgM, and IgG responses in COVID-19\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECellular \u0026amp; Molecular Immunology\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E) \u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E3\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_zP7WWIfzbyzvaM63L39cNV2juU_1XVH7wduFK9gcMNI.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}